"Diagnosis And Treatment Of Cancer Using Anti Lgr7 Antibody"

Abstract: With dedicated research, the present inventors discovered that not only the LGR7 gene but also the LGR7 protein are highly expressed in clear cell adenocarcinoma cells of ovarian cancer. Furthermore, the present inventors found that anti-LGR7 antibodies have antibody-dependent cell-mediated cytotoxicity (ADCC) activity and complement-dependent cytotoxicity (CDC) activity against LGR7-expressing cells. From the above findings, the present inventors discovered that the anti-LGR7 antibodies are useful for diagnosis, prevention, and treatment of primary and metastatic ovarian clear ceil adenocarcinoma.

Patent Information

Application #

Filing Date

17 June 2011

Publication Number

16/2012

Publication Type

INA

Invention Field

CHEMICAL

Status

Email

Parent Application

Applicants

THE UNIVERSITY OF TOKYO

3-1, HONGO 7-CHOME, BUNKYO-KU, TOKYO 1138654, JAPAN

FORERUNNER PHARMA RESEARCH CO., LTD.

2-16, KOMABA 4-CHOME, MEGURO-KU, TOKYO 1530041, JAPAN

Inventors

1. ABURATANI, HIROYUKI

C/O THE UNIVERSITY OF TOKYO, 3-1, HONGO 7-CHOME, TOKYO 1138654, JAPAN

2. UEHARA, YURIKO

C/O THE UNIVERSITY OF TOKYO, 3-1, HONGO 7-CHOME, TOKYO 1138654, JAPAN

3. FUNAHASHI, SHINICHI

C/O FORERUNNER PHARMA RESEARCH C., LTD, 2-16, KOMABA 4-CHOME, MEGURO-KU, TOKYO 1530041, JAPAN